Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AR101

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

- PMLiVE

Aimmune’s Palforzia is first peanut allergy drug cleared in US

Shares in the Nasdaq-listed biotech have spiked

- PMLiVE

Aimmune gets FDA panel backing for peanut allergy therapy

Step closer to becoming first approved treatment

- PMLiVE

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

- PMLiVE

Aimmune wins over ICER for peanut allergy product

Analysts predict blockbuster status for first-in-class

- PMLiVE

Aimmune preps EU filing for peanut allergy immunotherapy

Company set to be first to market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links